CARLSBAD, Calif., Dec. 6, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today positive results from a Phase 1 study with ISIS-APOCIIIRx. The results demonstrated that ISIS-APOCIIIRx treatment produced rapid, dose-dependent reductions of up to 78 percent in apolipoprotein C-III (apoC-III) protein and up to 44 percent in blood triglyceride levels. In this study, the drug also demonstrated a good safety profile and was well tolerated. These data will be presented today at the Cold Spring Harbor Laboratory 2nd RNA Therapeutics conference in New York.
"Patients with high levels of triglycerides are at significant risk of cardiovascular disease even if LDL-cholesterol levels are within acceptable/normal levels. High-risk patients, such as those with diabetes or metabolic syndrome, may also benefit from lowering their triglycerides. Unfortunately the needs of these patients are not adequately met and new treatment options are needed," said Frank Sacks, M.D., Professor of Cardiovascular Disease Prevention, Harvard School of Public Health. "ApoC-III itself is a pro-inflammatory protein and a key atherogenic lipid particle. In addition, recent data suggest that the inclusion of apoC-III in LDL particles increases their atherogenicity and therefore increases the risk of coronary artery disease. The combined benefit of lowering both apoC-III and triglycerides could potentially exceed that observed with current therapies that only reduce triglycerides."
The Phase 1 study of ISIS-APOCIIIRx was a blinded, randomized, placebo-controlled, dose-escalation study designed to assess the safety and pharmacokinetic profile of ISIS-APOCIIIRx in healthy volunteers and to assess the initial effects of the drug on baseline apoC-III and triglyceride levels. ISIS-APOCIIIRx was evaluated in sin